Trevena

Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) recently reported positive clinical data for TRV045, its selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator. The 3-part randomized, double-blind, placebo-controlled Phase 1 study …

Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator Read More

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) presented a poster at the recent 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit in Washington, …

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome Read More


medical news

Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer’s Disease

BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the U.S. Food and Drug Administration (FDA) recently authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer’s Disease …

Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer’s Disease Read More
Ocugen

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the publication of “A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects” which appeared in Frontiers in Immunology. BBV152, commercialized …

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology Read More